Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).

Bashir A, Mathilde Jacobsen S, Mølby Henriksen O, Broholm H, Urup T, Grunnet K, Andrée Larsen V, Møller S, Skjøth-Rasmussen J, Skovgaard Poulsen H, Law I.

Neuro Oncol. 2019 Sep 6. pii: noz166. doi: 10.1093/neuonc/noz166. [Epub ahead of print]

PMID:
31618420
2.
3.

Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.

Jena A, Taneja S, Gambhir A, Mishra AK, Dʼsouza MM, Verma SM, Hazari PP, Negi P, Jhadav GK, Sogani SK.

Clin Nucl Med. 2016 May;41(5):e228-36. doi: 10.1097/RLU.0000000000001152.

PMID:
26859208
4.

Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.

Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G, Erdem Z, Shah NJ, Fink GR, Coenen HH, Langen KJ.

J Nucl Med. 2013 Dec;54(12):2046-54. doi: 10.2967/jnumed.113.123836. Epub 2013 Oct 24.

5.

Potential for differentiation of glioma recurrence from radionecrosis using integrated 18F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation.

Sogani SK, Jena A, Taneja S, Gambhir A, Mishra AK, D'Souza MM, Verma SM, Hazari PP, Negi P, Jadhav GK.

Neurol India. 2017 Mar-Apr;65(2):293-301. doi: 10.4103/neuroindia.NI_101_16.

6.

Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?

Romagna A, Unterrainer M, Schmid-Tannwald C, Brendel M, Tonn JC, Nachbichler SB, Muacevic A, Bartenstein P, Kreth FW, Albert NL.

Radiat Oncol. 2016 Oct 21;11(1):139.

7.

Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy.

Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, Bauer E, Hamisch C, Ruge MI, Kocher M, Kuchelmeister K, Sellhaus B, Sabel M, Fink GR, Shah NJ, Langen KJ, Galldiks N.

Neuro Oncol. 2017 Feb 1;19(2):281-288. doi: 10.1093/neuonc/now149.

8.

The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord.

Tscherpel C, Dunkl V, Ceccon G, Stoffels G, Judov N, Rapp M, Meyer PT, Kops ER, Ermert J, Fink GR, Shah NJ, Langen KJ, Galldiks N.

Neuro Oncol. 2017 May 1;19(5):710-718. doi: 10.1093/neuonc/now243.

9.

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20.

PMID:
25411133
10.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

11.

Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, Todica A, Brendel M, Tonn JC, Bartenstein P, la Fougère C.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1105-14. doi: 10.1007/s00259-015-3276-2. Epub 2015 Dec 15.

PMID:
26666239
12.

18F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience.

Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, Galldiks N, Steinbach JP, Hattingen E, Langen KJ.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.234757. doi: 10.2967/jnumed.119.234757. [Epub ahead of print]

PMID:
31519802
13.

Monitoring of Tumor Growth with [(18)F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches.

Holzgreve A, Brendel M, Gu S, Carlsen J, Mille E, Böning G, Mastrella G, Unterrainer M, Gildehaus FJ, Rominger A, Bartenstein P, Kälin RE, Glass R, Albert NL.

Front Neurosci. 2016 Jun 14;10:260. doi: 10.3389/fnins.2016.00260. eCollection 2016.

14.

The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, Ceccon G, Dunkl V, Weinzierl M, Stoffel M, Sabel M, Fink GR, Shah NJ, Langen KJ.

Neuro Oncol. 2015 Sep;17(9):1293-300. doi: 10.1093/neuonc/nov088. Epub 2015 May 24.

15.

18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?

Fleischmann DF, Unterrainer M, Bartenstein P, Belka C, Albert NL, Niyazi M.

J Neurooncol. 2017 Apr;132(2):277-286. doi: 10.1007/s11060-016-2366-8. Epub 2017 Jan 19.

PMID:
28102485
16.

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.

Poulsen SH, Urup T, Grunnet K, Christensen IJ, Larsen VA, Jensen ML, Af Rosenschöld PM, Poulsen HS, Law I.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):373-381. doi: 10.1007/s00259-016-3494-2. Epub 2016 Aug 23.

17.

Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.

Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, Kaiser HJ, Filss CP, Fink GR, Coenen HH, Eble MJ, Piroth MD.

J Nucl Med. 2012 Jul;53(7):1048-57. doi: 10.2967/jnumed.111.098590. Epub 2012 May 29. Erratum in: J Nucl Med. 2013 Oct;54(10):1846.

18.

Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.

Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ.

Radiother Oncol. 2011 May;99(2):218-24. doi: 10.1016/j.radonc.2011.03.006. Epub 2011 Apr 16.

PMID:
21497925
19.

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

Galldiks N, Dunkl V, Ceccon G, Tscherpel C, Stoffels G, Law I, Henriksen OM, Muhic A, Poulsen HS, Steger J, Bauer EK, Lohmann P, Schmidt M, Shah NJ, Fink GR, Langen KJ.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2377-2386. doi: 10.1007/s00259-018-4082-4. Epub 2018 Jul 7.

PMID:
29982845
20.

Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

Pöpperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ, Kretzschmar HA, Tonn JC, Tatsch K.

J Nucl Med. 2006 Mar;47(3):393-403. Erratum in: J Nucl Med. 2006 May;47(5):806.

Supplemental Content

Support Center